Valuation: Bonesupport Holding AB

Market Cap 14.08B 1.42B 1.25B 1.18B 1.07B 2.01B 136B 2.02B 5.45B 69.51B 5.33B 5.22B 223B P/E 2026 *
43.8x
P/E 2027 * 27.9x
Enterprise Value 13.54B 1.36B 1.2B 1.13B 1.03B 1.93B 131B 1.94B 5.24B 66.83B 5.12B 5.01B 215B EV / Sales 2026 *
9.07x
EV / Sales 2027 * 6.69x
Free-Float
89.54%
Yield 2026 *
0.68%
Yield 2027 * 1%
1 day-12.12%
1 week-12.12%
Current month-8.61%
1 month-8.61%
3 months+0.32%
6 months+2.23%
Current year+8.45%
1 week 21.47
Extreme 21.468
21.47
1 month 21.47
Extreme 21.468
24.43
Current year 19
Extreme 19
28.57
1 year 18.57
Extreme 18.57
31.3
3 years 15.74
Extreme 15.74
35
5 years 3.83
Extreme 3.83
35
10 years 3.83
Extreme 3.83
35
Manager TitleAgeSince
Chief Executive Officer 49 2025-08-31
Director of Finance/CFO 63 2018-10-31
Chief Operating Officer 51 2021-11-30
Director TitleAgeSince
Director/Board Member 68 2009-12-31
Chairman 70 2016-12-14
Chairman 71 2019-05-13
Change 5-day change 1-year change 3-year change Capi.($)
-12.12%-12.12% - - 1.42B
-2.08%+29.11%+712.09%+100.00% 79.4B
-1.97%+0.41%+39.75%-5.35% 78.69B
+2.80%+2.02%-8.59%-27.82% 59.52B
-0.89%+0.05%-6.77%+172.40% 46.58B
-1.80%-2.29%-11.16%+30.46% 46.53B
-0.35%+5.61%+65.68%-11.62% 33.63B
-0.22%-1.13%+49.81%+109.59% 25.11B
-3.56%-6.10%+2.72%+140.98% 22.13B
+0.46%-1.13%+56.98%+96.68% 15.31B
Average -2.07%+4.05%+100.06%+67.26% 45.21B
Weighted average by Cap. -1.07%+6.45%+154.13%+54.74%

Financials

2026 *2027 *
Net sales 1.49B 151M 132M 125M 114M 213M 14.43B 214M 578M 7.37B 565M 553M 23.69B 1.98B 199M 175M 165M 150M 282M 19.1B 284M 765M 9.76B 748M 732M 31.36B
Net income 319M 32.14M 28.2M 26.64M 24.27M 45.44M 3.08B 45.76M 123M 1.57B 121M 118M 5.06B 504M 50.78M 44.56M 42.09M 38.36M 71.8M 4.87B 72.31M 195M 2.49B 191M 187M 7.99B
Net Debt -543M -54.75M -48.05M -45.38M -41.35M -77.41M -5.25B -77.96M -210M -2.68B -206M -201M -8.62B -856M -86.28M -75.71M -71.5M -65.16M -122M -8.27B -123M -331M -4.22B -324M -317M -13.58B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
171
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
215.00SEK
Average target price
356.58SEK
Spread / Average Target
+65.85%

Quarterly revenue - Rate of surprise